See more : ValueMax Group Limited (T6I.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Oncopeptides AB (publ) (ONPPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncopeptides AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Phoenix New Media Limited (FENG) Income Statement Analysis – Financial Results
- Starpharma Holdings Limited (SPL.AX) Income Statement Analysis – Financial Results
- ETAO International Co., Ltd. (ETAOF) Income Statement Analysis – Financial Results
- PVH Corp. (0KEQ.L) Income Statement Analysis – Financial Results
- Imugene Limited (IMU.AX) Income Statement Analysis – Financial Results
Oncopeptides AB (publ) (ONPPF)
About Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.22M | 8.36M | 118.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | -1.08M | 6.00K | 53.12M | 14.40M | 4.54M | 345.00K | 271.00K | 24.07K | 0.00 | 0.00 |
| Gross Profit | 36.30M | 8.35M | 65.17M | -14.40M | -4.54M | -345.00K | -271.00K | -24.07K | 0.00 | 0.00 |
| Gross Profit Ratio | 103.06% | 99.93% | 55.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 106.95M | 217.66M | 679.93M | 866.21M | 548.27M | 322.05M | 197.77M | 89.73M | 43.85M | 28.07M |
| General & Administrative | 68.88M | 84.09M | 175.46M | 197.66M | 72.05M | 55.30M | 34.69M | -17.49M | 9.50M | -5.88M |
| Selling & Marketing | 119.60M | 58.10M | 698.35M | 456.53M | 127.41M | 51.13M | 15.16M | 630.00K | 0.00 | 0.00 |
| SG&A | 188.48M | 142.20M | 873.81M | 654.19M | 199.46M | 106.42M | 49.85M | -17.49M | 9.50M | -5.88M |
| Other Expenses | -5.68M | 3.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 289.75M | 357.70M | 1.49B | 1.59B | 739.39M | 419.30M | 247.62M | 114.48M | 53.35M | 33.11M |
| Cost & Expenses | 288.67M | 357.71M | 1.54B | 1.59B | 739.39M | 419.30M | 247.62M | 114.48M | 53.35M | 33.11M |
| Interest Income | 8.59M | 2.62M | 492.00K | 322.00K | 528.00K | 0.00 | 0.00 | 1.01K | 10.00K | 16.38K |
| Interest Expense | 5.79M | 883.00K | 948.00K | 1.49M | 528.00K | 2.00K | 0.00 | 305.00 | 1.00K | 432.00 |
| Depreciation & Amortization | 11.04M | 17.18M | 21.37M | 14.40M | 4.54M | 345.00K | 271.00K | 24.07K | 7.00K | 7.37K |
| EBITDA | -231.62M | -319.64M | -1.41B | -1.52B | -747.35M | -419.79M | -247.35M | -114.46M | -53.34M | -33.10M |
| EBITDA Ratio | -657.64% | -3,825.69% | -1,188.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -253.45M | -349.35M | -1.42B | -1.59B | -739.39M | -419.30M | -247.62M | -114.48M | -53.35M | -33.11M |
| Operating Income Ratio | -719.61% | -4,181.33% | -1,201.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.00M | 11.67M | -455.00K | -1.16M | -528.00K | 8.34M | 0.00 | 36.07K | 9.00K | 15.94K |
| Income Before Tax | -248.45M | -337.68M | -1.42B | -1.59B | -739.92M | -419.30M | -247.62M | -114.45M | -53.34M | -33.09M |
| Income Before Tax Ratio | -705.41% | -4,041.65% | -1,201.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 664.00K | 271.00K | 8.95M | 2.25M | 785.00K | 147.00K | -38.00K | 36.38K | 10.00K | 16.38K |
| Net Income | -249.11M | -337.95M | -1.43B | -1.59B | -740.71M | -419.45M | -247.62M | -114.45M | -53.34M | -33.09M |
| Net Income Ratio | -707.30% | -4,044.90% | -1,209.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.76 | -4.11 | -19.00 | -25.57 | -14.33 | -9.77 | -6.39 | -2.95 | -1.37 | -0.85 |
| EPS Diluted | -2.76 | -4.11 | -19.00 | -25.57 | -14.33 | -9.77 | -6.39 | -2.95 | -1.37 | -0.85 |
| Weighted Avg Shares Out | 90.39M | 82.32M | 75.29M | 62.37M | 51.70M | 42.93M | 38.78M | 38.83M | 38.83M | 38.83M |
| Weighted Avg Shares Out (Dil) | 90.39M | 82.32M | 75.29M | 62.37M | 51.70M | 42.93M | 38.78M | 38.83M | 38.83M | 38.83M |
Oncopeptides presents new data from OCEAN and PORT study - abstracts online
After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold
Source: https://incomestatements.info
Category: Stock Reports